HLB, Stock Price Down 3.06% at This Time... Institutional Investors Net Sell 200,070 Shares in Last 5 Days

HLB is trading at 94,900 KRW as of 2:30 PM on the 11th, down 3.06% from the previous day. The trading volume is 745,742 shares, which is 55.0% of the previous day's volume. HLB is known as a manufacturer of lifeboats and a manufacturer and installer of fiberglass pipes.

On January 8, Byungyong Oh, a researcher at Hanyang Securities, stated, "The Phase 2 clinical trial results of the brain tumor cell therapy ‘ITI1000’ are scheduled to be announced in the first half of the year. The Phase 2 clinical trial results of ‘Lenvatinib’ for cholangiocarcinoma are also expected in the first half of the year. Patient recruitment for the global Phase 3 trial of ‘Lenvatinib + Camrelizumab’ has surpassed 95%. The NDA for Lenvatinib’s gastric cancer in 2020 was continuously delayed due to COVID-19 issues, and there were no significant events such as clinical trial result announcements or technology exports. Therefore, the stock price remained sluggish. Finally, clinical results are being announced. Positive stock price trends are expected going forward." He set HLB’s target price at 144,500 KRW.

Over the past five days, individual investors have net purchased 81,164 shares of HLB, while foreigners and institutions have net purchased 82,806 shares and net sold 200,700 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.